10
Participants
Start Date
August 1, 2017
Primary Completion Date
May 31, 2022
Study Completion Date
October 1, 2024
MiniMed 670G system
Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels \< 70 mg/dl.
Clinical and Translational Research Center, Hospital of University of Pennsylvania, Philadelphia
Rodebaugh Diabetes Center, University of Pennsylvania, Philadelphia
University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism, Philadelphia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
University of Pennsylvania
OTHER